Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. doi: 10.1073/pnas.0903474106. Epub 2009 Oct 7.

    The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

    Source

    The Lautenberg Center for General and Tumor Immunology, IMRIC, Hadassah Medical School, Hebrew University, Jerusalem 91120, Israel.

    Abstract

    NK cell cytotoxicity is controlled by numerous NK inhibitory and activating receptors. Most of the inhibitory receptors bind MHC class I proteins and are expressed in a variegated fashion. It was recently shown that TIGIT, a new protein expressed by T and NK cells binds to PVR and PVR-like receptors and inhibits T cell activity indirectly through the manipulation of DC activity. Here, we show that TIGIT is expressed by all human NK cells, that it binds PVR and PVRL2 but not PVRL3 and that it inhibits NK cytotoxicity directly through its ITIM. Finally, we show that TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.

    PMID:
    19815499
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2764881
    Free PMC Article

    Images from this publication.See all images (6)Free text

    Fig. 1.
    Fig. 2.
    Fig. 3.
    Fig. 4.
    Fig. 5.
    Fig. 6.

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk